Details for New Drug Application (NDA): 211427
NDA 211427 describes DESVENLAFAXINE SUCCINATE, which is a drug marketed by Actavis Labs Fl, Alembic, Hikma, Lupin, Macleods Pharms, Pharmobedient, Platinum, Rubicon Research, Yichang Humanwell, and Zydus Pharms, and is included in eleven NDAs. It is available from twenty suppliers. Additional details are available on the DESVENLAFAXINE SUCCINATE profile page.
The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There is one drug master file entry for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There is one drug master file entry for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
Summary for 211427
| Tradename: | DESVENLAFAXINE SUCCINATE |
| Applicant: | Macleods Pharms |
| Ingredient: | desvenlafaxine succinate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 211427
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 211427 | ANDA | Macleods Pharmaceuticals Limited | 33342-388 | 33342-388-07 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (33342-388-07) |
| DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 211427 | ANDA | Macleods Pharmaceuticals Limited | 33342-388 | 33342-388-10 | 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (33342-388-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 50MG BASE | ||||
| Approval Date: | Jan 15, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Jan 15, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
